Literature DB >> 7737909

Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.

H Naitoh1, Y Eguchi, H Ueyama, M Kodama, T Hattori.   

Abstract

We examined the localization of urokinase-type plasminogen activator (u-PA), plasminogen activator inhibitors (PAI-1 and PAI-2) and plasminogen (plg) in 26 cases of colon cancer by immunohistochemical staining. The u-PA antigen was detected in the cytoplasm of cancer cells (18/26) and stromal cells adjacent to cancer tissues (9/26). The localization of u-PA mRNA examined by in situ hybridization was consistent with that of u-PA antigen. The PAI-1 antigen was detected in fibroblasts and endothelial cells (22/26), while PAI-2 antigen was found in cancer cells (20/26). The plg antigen was seen in the extracellular matrix of the cancer stroma. The u-PA expression in cancer cells was significantly more frequently detected in cases with lymph node metastasis than in cases without metastasis. In either PAI-1- or PAI-2-expressing cases, lymph node metastasis seemed to be restrained. These findings indicate that cancer cells themselves produce u-PA, and suggest that u-PA converts plg into plasmin, which dissolves the extracellular matrix surrounding cancer cells, resulting in cancer invasion and metastasis. PAI-1 and PAI-2 may have inhibitory actions on cancer invasion and metastasis mediated by u-PA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7737909      PMCID: PMC5920580          DOI: 10.1111/j.1349-7006.1995.tb02987.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  35 in total

1.  Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.

Authors:  P H Quax; R T van Leeuwen; H W Verspaget; J H Verheijen
Journal:  Cancer Res       Date:  1990-03-01       Impact factor: 12.701

2.  An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells.

Authors:  S A Rabbani; J Desjardins; A W Bell; D Banville; A Mazar; J Henkin; D Goltzman
Journal:  Biochem Biophys Res Commun       Date:  1990-12-31       Impact factor: 3.575

3.  Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.

Authors:  K Huber; J C Kirchheimer; A Sedlmayer; C Bell; D Ermler; B R Binder
Journal:  Cancer Res       Date:  1993-04-15       Impact factor: 12.701

4.  The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.

Authors:  C Pyke; P Kristensen; E Ralfkiaer; J Eriksen; K Danø
Journal:  Cancer Res       Date:  1991-08-01       Impact factor: 12.701

5.  Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum.

Authors:  C F Sier; C Fellbaum; H W Verspaget; M Schmitt; G Griffioen; H Graeff; H Hôfler; C B Lamers
Journal:  Histopathology       Date:  1991-09       Impact factor: 5.087

6.  Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways.

Authors:  A M Montgomery; Y A De Clerck; K E Langley; R A Reisfeld; B M Mueller
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

7.  Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization.

Authors:  C Pyke; E Ralfkiaer; P Huhtala; T Hurskainen; K Danø; K Tryggvason
Journal:  Cancer Res       Date:  1992-03-01       Impact factor: 12.701

8.  Phosphorylation of a surface receptor bound urokinase-type plasminogen activator in a human metastatic carcinomatous cell line.

Authors:  K Takahashi; H C Kwaan; K Ikeo; E Koh
Journal:  Biochem Biophys Res Commun       Date:  1992-02-14       Impact factor: 3.575

9.  Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.

Authors:  M V Cubellis; T C Wun; F Blasi
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

Review 10.  Recent developments in the cell biology of basic fibroblast growth factor.

Authors:  D B Rifkin; D Moscatelli
Journal:  J Cell Biol       Date:  1989-07       Impact factor: 10.539

View more
  3 in total

1.  Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.

Authors:  H Shiomi; Y Eguchi; T Tani; M Kodama; T Hattori
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas.

Authors:  I Sordat; P Chaubert; P Protiva; L Guillou; L Mazzucchelli; E Saraga; J Benhattar; C Trân-Thang; A L Blum; G Dorta; B Sordat
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

3.  Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis.

Authors:  H Yoshino; Y Endo; Y Watanabe; T Sasaki
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.